Mutation-specific T cells for immunotherapy of gliomas

New England Journal of Medicine

Volumn 372, Issue 20, 2015, Pages 1956-1958

  Melief, Cornelis J M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; HLA ANTIGEN CLASS 2; ISOCITRATE DEHYDROGENASE 1; NEOANTIGEN; PEPTIDE VACCINE; PROGRAMMED DEATH 1 RECEPTOR; RNA VACCINE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; CANCER VACCINE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; MUTANT PROTEIN;

ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DOWN REGULATION; EPITOPE MAPPING; GENE MUTATION; GLIOMA; IMMUNE RESPONSE; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; SOMATIC MUTATION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; DISEASE MODEL; GENETICS; HELPER CELL; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MOUSE; MUTATION; PROCEDURES;

ANIMALS; CANCER VACCINES; DISEASE MODELS, ANIMAL; GLIOMA; HUMANS; IMMUNOTHERAPY; ISOCITRATE DEHYDROGENASE; MICE; MUTANT PROTEINS; MUTATION; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84929346805     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr1501818     Document Type: Article

References (5)

1. Schumacher T, Bunse L, Pusch S, et al. A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 2014;512:324-7.
2. Kast WM, Bronkhorst AM, de Waal LP, Melief CJ. Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection - protection by T cells is MHC-restricted and MHC-regulated; a model for MHC-disease associations. J Exp Med 1986;164:723-38.
3. Quezada SA, Simpson TR, Peggs KS, et al. Tumor-reactive CD4 (+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010;207:637-50.
4. Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014;371:2189-99.
5. Gubin MM, Zhang X, Schuster H, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014;515:577-81.